US-based Boston Scientific has completed the acquisition of Claret Medical for $270m.

Claret Medical will receive $220m in cash from Boston Scientific and $50m as a potential reimbursement-based milestone payment.

Based in the US, Claret Medical is a manufacturer of cerebral vascular protection systems. The company’s Sentinel System, a cerebral embolic protection system, was granted new technology add-on payment (NTAP) designation by the US Centres for Medicare and Medicaid Services (CMS).

The Sentinel System has also received a European CE-Mark this year and US FDA clearance last year.

Lincare Holdings Inc has completed the acquisition of Specialized Medical Services Inc from Riverside Co for an undisclosed sum.

Based in the US, Lincare Holdings is an oxygen and respiratory therapy services provider, while Specialized Medical Services, also based in the US, is a medical devices provider for respiratory care services.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The company will purchase 100% shares of Nash Pharma in consideration for the issuance of the former’s 15.8 million common shares.”

Jones Day has been appointed as the legal advisor to Riverside for the transaction.

Breathtec Biomedical Inc has inked a letter of intent (LOI) to purchase all the outstanding shares of Nash Pharmaceuticals Inc.

Breathtec will sign a definitive agreement with Nash Pharma pursuant to the LOI, where the former will complete a consolidation of its securities on a 2-to-1 basis, before the transaction closure.

The company will purchase 100% shares of Nash Pharma in consideration for the issuance of the former’s 15.8 million common shares. The company will also issue 14.8 million additional warrants at an equal exercise price of the target company’s warrants.

Breathtec also plans to complete a private placement of securities to raise proceeds of up to C$1m ($0.76). The funds raised will be used towards the development of Nash Pharma’s business.

Based in Canada, Breathtec is a developer of medical devices for the early screening of life-threatening diseases, while Nash Pharma, also based in Canada, is a clinical-stage pharmaceutical company.